Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

George Hruby

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4193-9682; OpenAlex author ID A5088299044. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. SPAN-C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1111/1754-9485.13874↗
  2. Evaluation of deep learning based implanted fiducial markers tracking in pancreatic cancer patients. Co-author DOI 10.1088/2057-1976/acb550↗
  3. The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients' survival. Co-author DOI 10.1186/s12957-022-02803-y↗
  4. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  5. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Co-author DOI 10.1097/pas.0000000000001601↗
  6. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. Co-author DOI 10.1111/ans.17151↗
  7. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001472↗
  8. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume r… Co-author DOI 10.1016/j.ejso.2017.06.012↗
  9. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the trea… Co-author DOI 10.1038/bjc.2011.526↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 7 shared papers, 2017–2025 · strength 0.87
  2. Anubhav Mittal · 7 shared papers, 2017–2025 · strength 0.87
  3. Stephen John Clarke · 6 shared papers, 2017–2025 · strength 0.74
  4. Nick Pavlakis · 6 shared papers, 2017–2025 · strength 0.74
  5. Anthony James Gill · 5 shared papers, 2017–2022 · strength 0.52
  6. Christopher Bahdah Nahm · 4 shared papers, 2017–2022 · strength 0.41
  7. Jeremy Booth · 2 shared papers, 2023–2025 · strength 0.38
  8. Terence C. Chua · 3 shared papers, 2017–2021 · strength 0.26
  9. Joseph C. Y. Chan · 1 shared paper, 2025 · strength 0.22
  10. Nigel Balfour Jamieson · 2 shared papers, 2020–2021 · strength 0.21
  11. Abdella M. Ahmed · 1 shared paper, 2023 · strength 0.17
  12. Maxwell A. Jambor · 1 shared paper, 2022 · strength 0.15
  13. Malinda Itchins · 2 shared papers, 2017–2020 · strength 0.15
  14. Andrew Ohyama Parsonson · 1 shared paper, 2021 · strength 0.13
  15. Neil Donald Merrett · 1 shared paper, 2021 · strength 0.13
  16. Charbel Sandroussi · 1 shared paper, 2021 · strength 0.13
  17. Peter Grimison · 1 shared paper, 2021 · strength 0.13
  18. Angela S. Y. Chou · 1 shared paper, 2021 · strength 0.11
  19. Sumit Sahni · 1 shared paper, 2021 · strength 0.11
  20. Sarah Maloney · 1 shared paper, 2021 · strength 0.11
  21. David Lok Hang Chan · 1 shared paper, 2021 · strength 0.11
  22. Asanka Rohan Wijetunga · 1 shared paper, 2021 · strength 0.11
  23. Matthew H. Wong · 1 shared paper, 2017 · strength 0.05
  24. David Goldstein · 1 shared paper, 2012 · strength 0.02
  25. Nigel A. Spry · 1 shared paper, 2012 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.